View ValuationMedios 将来の成長Future 基準チェック /36Medios利益と収益がそれぞれ年間34%と6.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に8.5% 31.6%なると予測されています。主要情報34.0%収益成長率31.60%EPS成長率Healthcare 収益成長17.8%収益成長率6.2%将来の株主資本利益率8.47%アナリストカバレッジLow最終更新日21 Jun 2024今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jul 01Medios AG Closes the Facility of Its Wholly Owned Subsidiary, Medios Solutions Aschaffenburg GmbHMedios AG is closing the facility of its wholly owned subsidiary, Medios Solutions Aschaffenburg GmbH, and consolidated patient-specific manufacturing at the remaining locations in its Germany-wide network. Production had already been relocated, and supplies to pharmacies and hospitals are guaranteed. Aschaffenburg most recently accounted for approximately 10% of the production volume of the Medios Group’s German manufacturing facilities. The measure affects 32 employees, for whom Medios is seeking to provide fair compensation. The business of patient-specific formulations is under sustained margin pressure – particularly due to price regulatory adjustments – which the company is now countering with measures to increase efficiency. In Germany, Medios operates up until now a network of six GMP manufacturing facilities for patient-specific therapies (GMP stands for “Good Manufacturing Practice,” which entails mandatory production standards and validated quality management). The Aschaffenburg site had recently been operating at below-average profitability amid declining capacity utilization. Against this backdrop, continued economic operation was no longer feasible. Structural renovation work currently required at the site has accelerated the implementation of this decision. The site closure is part of the company’s Operational Excellence Program, which aims to sustainably strengthen profitability.お知らせ • Apr 30Medios AG, Annual General Meeting, Jun 10, 2026Medios AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time.お知らせ • Dec 05+ 3 more updatesMedios AG to Report Q1, 2026 Results on May 12, 2026Medios AG announced that they will report Q1, 2026 results on May 12, 2026お知らせ • Apr 15Medios AG, Annual General Meeting, May 27, 2025Medios AG, Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time.お知らせ • Jun 08Medios AG (XTRA:ILM1) acquired Ceban B.V. from Bencis Capital Partners B.V.Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for €259 million on March 18, 2024. The purchase price for the transaction includes a cash component of €235.3 million and 1.7 million new Medios shares valued approx. €23.9 million. The newly issued shares will be subject to a hard lock-up period of 24 months. The purchase price is financed by Medios from existing cash and an already committed credit facility. The 1.7 million new shares will be issued out of authorized capital against contributions in kind. Ceban had a preliminary revenue of €160 million in 2023. The preliminary EBITDA-adjusted amounts to €29 million in 2023. Ceban will continue to operate under its own brand names. Ceban’s strong and experienced management team has committed to remain fully involved to further drive growth in already existing markets and in new geographies within Europe. The completion of the transaction is subject to the fulfilment of customary closing conditions. The closing of the transaction is expected for the second quarter of 2024. The transaction has attractive multiple and immediately accretive to EBITDA pre and EBITDA pre margin.Jefferies LLC acted as financial advisor to Ceban. Dirk Besse and Sebastian Schwalme of Morrison & Foerster LLP acted as legal advisors for Medios AG. Danielle du Bois-Buné, Bastiaan van Rath, Hein van den Bos, Alexander Fortuin, Matthijs Dols, Maria Benbrahim, Mariëtte Vis, Chantal van Dam, Robert Masman, Tom van Duuren, Michael Schlitt, Susanne Ries, Sebastian Biller, Karolin Hiller, Fabien Roy, Falk Schöning of Hogan Lovells International Llp acted as sell-side legal advisor to Bencis Capital Partners B.V.Medios AG (XTRA:ILM1) completed the acquisition of Ceban B.V. from Bencis Capital Partners B.V. on June 6, 2024. The conditions required for the closing of the transaction were fully met. Ceban B.V. will be included in the scope of consolidation of Medios AG as of June 1, 2024.お知らせ • Mar 20Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million.Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million on March 18, 2024. The purchase price for the transaction includes a cash component of €235.3 million and 1.7 million new Medios shares valued approx. €23.9 million. The newly issued shares will be subject to a hard lock-up period of 24 months. The purchase price is financed by Medios from existing cash and an already committed credit facility. The 1.7 million new shares will be issued out of authorized capital against contributions in kind. Ceban had a preliminary revenue of €160 million in 2023. The preliminary EBITDA-adjusted amounts to €29 million in 2023. Ceban will continue to operate under its own brand names. Ceban’s strong and experienced management team has committed to remain fully involved to further drive growth in already existing markets and in new geographies within Europe. The completion of the transaction is subject to the fulfilment of customary closing conditions. The closing of the transaction is expected for the second quarter of 2024. Jefferies LLC acted as financial advisor to Ceban.お知らせ • Jan 06Medios AG, Annual General Meeting, Jun 26, 2024Medios AG, Annual General Meeting, Jun 26, 2024.お知らせ • Dec 08+ 1 more updateMedios AG to Report Q2, 2024 Results on Aug 13, 2024Medios AG announced that they will report Q2, 2024 results on Aug 13, 2024業績と収益の成長予測OTCPK:MEDO.F - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20262,260495570512/31/20252,167444761512/31/20242,01229455753/31/20241,810188485N/A12/31/20231,785191516N/A9/30/20231,743192830N/A6/30/20231,67318-51-48N/A3/31/20231,650181114N/A12/31/20221,612183237N/A9/30/20221,581133239N/A6/30/20221,516113242N/A3/31/20221,436102538N/A12/31/20211,35974962N/A9/30/20211,16311-15-5N/A6/30/20219699-24-15N/A3/31/20217806-12-6N/A12/31/20206276-43-38N/A9/30/2020599602N/A6/30/2020582925N/A3/31/202056610-14-11N/A12/31/201951810-30N/A9/30/2019464903N/A6/30/20194137-3-1N/A3/31/20193716-4-2N/A12/31/20183294-5-3N/A9/30/20183054-3-1N/A6/30/20182823-22N/A3/31/20182684-31N/A12/31/20172544N/A1N/A9/30/20172241N/A-2N/A6/30/2017193-2N/A-5N/A3/31/2017163-3N/A-3N/A12/31/2016133-3N/A-2N/A12/31/2015581N/A1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MEDO.Fの予測収益成長率 (年間34% ) は 貯蓄率 ( 2.4% ) を上回っています。収益対市場: MEDO.Fの収益 ( 34% ) はUS市場 ( 16.8% ) よりも速いペースで成長すると予測されています。高成長収益: MEDO.Fの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: MEDO.Fの収益 ( 6.2% ) US市場 ( 12.8% ) よりも低い成長が予測されています。高い収益成長: MEDO.Fの収益 ( 6.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MEDO.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 8.5 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/07/30 02:11終値2024/05/03 00:00収益2024/03/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medios AG 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Michael HeiderBerenbergMichael KuhnDeutsche BankMartin ComtesseJefferies LLC7 その他のアナリストを表示
お知らせ • Jul 01Medios AG Closes the Facility of Its Wholly Owned Subsidiary, Medios Solutions Aschaffenburg GmbHMedios AG is closing the facility of its wholly owned subsidiary, Medios Solutions Aschaffenburg GmbH, and consolidated patient-specific manufacturing at the remaining locations in its Germany-wide network. Production had already been relocated, and supplies to pharmacies and hospitals are guaranteed. Aschaffenburg most recently accounted for approximately 10% of the production volume of the Medios Group’s German manufacturing facilities. The measure affects 32 employees, for whom Medios is seeking to provide fair compensation. The business of patient-specific formulations is under sustained margin pressure – particularly due to price regulatory adjustments – which the company is now countering with measures to increase efficiency. In Germany, Medios operates up until now a network of six GMP manufacturing facilities for patient-specific therapies (GMP stands for “Good Manufacturing Practice,” which entails mandatory production standards and validated quality management). The Aschaffenburg site had recently been operating at below-average profitability amid declining capacity utilization. Against this backdrop, continued economic operation was no longer feasible. Structural renovation work currently required at the site has accelerated the implementation of this decision. The site closure is part of the company’s Operational Excellence Program, which aims to sustainably strengthen profitability.
お知らせ • Apr 30Medios AG, Annual General Meeting, Jun 10, 2026Medios AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time.
お知らせ • Dec 05+ 3 more updatesMedios AG to Report Q1, 2026 Results on May 12, 2026Medios AG announced that they will report Q1, 2026 results on May 12, 2026
お知らせ • Apr 15Medios AG, Annual General Meeting, May 27, 2025Medios AG, Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Jun 08Medios AG (XTRA:ILM1) acquired Ceban B.V. from Bencis Capital Partners B.V.Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for €259 million on March 18, 2024. The purchase price for the transaction includes a cash component of €235.3 million and 1.7 million new Medios shares valued approx. €23.9 million. The newly issued shares will be subject to a hard lock-up period of 24 months. The purchase price is financed by Medios from existing cash and an already committed credit facility. The 1.7 million new shares will be issued out of authorized capital against contributions in kind. Ceban had a preliminary revenue of €160 million in 2023. The preliminary EBITDA-adjusted amounts to €29 million in 2023. Ceban will continue to operate under its own brand names. Ceban’s strong and experienced management team has committed to remain fully involved to further drive growth in already existing markets and in new geographies within Europe. The completion of the transaction is subject to the fulfilment of customary closing conditions. The closing of the transaction is expected for the second quarter of 2024. The transaction has attractive multiple and immediately accretive to EBITDA pre and EBITDA pre margin.Jefferies LLC acted as financial advisor to Ceban. Dirk Besse and Sebastian Schwalme of Morrison & Foerster LLP acted as legal advisors for Medios AG. Danielle du Bois-Buné, Bastiaan van Rath, Hein van den Bos, Alexander Fortuin, Matthijs Dols, Maria Benbrahim, Mariëtte Vis, Chantal van Dam, Robert Masman, Tom van Duuren, Michael Schlitt, Susanne Ries, Sebastian Biller, Karolin Hiller, Fabien Roy, Falk Schöning of Hogan Lovells International Llp acted as sell-side legal advisor to Bencis Capital Partners B.V.Medios AG (XTRA:ILM1) completed the acquisition of Ceban B.V. from Bencis Capital Partners B.V. on June 6, 2024. The conditions required for the closing of the transaction were fully met. Ceban B.V. will be included in the scope of consolidation of Medios AG as of June 1, 2024.
お知らせ • Mar 20Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million.Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million on March 18, 2024. The purchase price for the transaction includes a cash component of €235.3 million and 1.7 million new Medios shares valued approx. €23.9 million. The newly issued shares will be subject to a hard lock-up period of 24 months. The purchase price is financed by Medios from existing cash and an already committed credit facility. The 1.7 million new shares will be issued out of authorized capital against contributions in kind. Ceban had a preliminary revenue of €160 million in 2023. The preliminary EBITDA-adjusted amounts to €29 million in 2023. Ceban will continue to operate under its own brand names. Ceban’s strong and experienced management team has committed to remain fully involved to further drive growth in already existing markets and in new geographies within Europe. The completion of the transaction is subject to the fulfilment of customary closing conditions. The closing of the transaction is expected for the second quarter of 2024. Jefferies LLC acted as financial advisor to Ceban.
お知らせ • Jan 06Medios AG, Annual General Meeting, Jun 26, 2024Medios AG, Annual General Meeting, Jun 26, 2024.
お知らせ • Dec 08+ 1 more updateMedios AG to Report Q2, 2024 Results on Aug 13, 2024Medios AG announced that they will report Q2, 2024 results on Aug 13, 2024